MedKoo product information:

 Tegafur 

Tegafur (INN) is a chemotherapeutic 5-FU prodrug used in the treatment of cancers. It is a component of tegafur-uracil. When metabolized, it becomes 5-FU. Tegafur-uracil is a formulated therapeutic oral agent consisting of a combination of the 5-fluorouracil (5-FU) congener prodrug tegafur (tetrahydrofuranyl-5-fluorouracil) and uracil (1:4). The high concentration of uracil reversibly inhibits the uracil-reducing enzyme dihydropyrimidine dehydrogenase (DPD), thereby inhibiting first-pass DPD-mediated hepatic metabolism of the uracil analogue 5-FU and permitting administration of 5-FU as the orally bioavailable prodrug tegafur. Tegafur is bioactivated to 5-FU by liver microsomal cytochrome P450 enzymes. 5-FU is subsequently converted into its active metabolites 5-fluoro-deoxyuridine-monophosphate (FdUMP) and 5-fluorouridine-triphosphate (FUTP) intracellularly; these metabolites inhibit the enzyme thymidylate synthase and intercalate into RNA, resulting in decreased thymidine synthesis, reduced DNA synthesis, disrupted RNA function, and tumor cell cytotoxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

The UFT combination was developed in the 1980s using tegafur, a pro-5FU drug. Tested and approved in various countries as a therapy for advanced colorectal cancer to replace 5FU, "patients appeared strongly to prefer treatment with UFT/LV over 5-FU/LV."  and has a low cost.  UFT is a first generation DIF, or DPD (DihydroPyrimidine Dehydrogenase) Inhibitory Flouropyrimidine drug. UFT is an oral agent with combines uracil, a competitive inhibitor of DPD, with the 5-FU prodrug tegafur in a 4:1 molar ratio. Excess uracil competes with 5-FU for DPD, thus inhibiting 5-FU catabolism.

The tegafur is taken up by the cancer cells and breaks down into 5-FU, a substance that kills tumor cells. The uracil causes higher amounts of 5-FU to stay inside the cells and kill them. Ftorafur is a type of antimetabolite. The uracil has also been stated to help protect the gastrointestinal tract from 5-FU toxicity and the related metabolites, with less side effects than 5-FU and other 5-FU related (pro)drugs. Trials using UFT for cancer treatment include pancreatic cancer, colorectal cancer, liver cancer, adenocarcinoma of the lung and breast cancer with significant gains over existing treatments, with reduced side effects, improved quality of life, improved disease free survival and/or overall survival. In Japan, China and Korea, papers cite improved success utilizing UFT with cimetidine and/or PSK, both in trials with advanced colorectal cancer, and refractory individual cases of solid tumors with dismal prognoses.

UFT has been administered on a continuous daily basis for 6 to 36 months at 300-400 mg per day in divided doses, in cycles of 5 days dosed at 300 mg/m2 per day, followed by the weekend off, or in cycles of 28 days dosed at 300-600 mg/m2 per day, followed by a week off. The low side effect profile of UFT allows continuous, extended treatments of several years. It is marketed by companies including Merck Serono, Korea United and Taiho, mostly in Asia, Europe, South America, Central America and South Africa.
It is sold under a variety of names including: Tegafur-uracil, UFT, Ftorafur, Tefudex, Ufur and Uftoral. (source: http://en.wikipedia.org/wiki/Tegafur-uracil).

 1: Shinoto M, Shioyama Y, Sasaki T, Nakamura K, Ohura H, Toh Y, Higaki Y, Yamaguchi T, Ohnishi K, Atsumi K, Hirata H, Honda H. Clinical Results of Definitive Chemoradiotherapy for Patients With Synchronous Head and Neck Squamous Cell Carcinoma and Esophageal Cancer. Am J Clin Oncol. 2010 Aug 3. [Epub ahead of print] PubMed PMID: 20686402.

2: Sugiyama E, Kaniwa N, Kim SR, Hasegawa R, Saito Y, Ueno H, Okusaka T, Ikeda M, Morizane C, Kondo S, Yamamoto N, Tamura T, Furuse J, Ishii H, Yoshida T, Saijo N, Sawada J. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet. 2010 Aug 1;49(8):549-58. doi: 10.2165/11532970-000000000-00000. PubMed PMID: 20608756.

3: Arias JL, López-Viota M, Gallardo V, Adolfina Ruiz M. Chitosan nanoparticles as a new delivery system for the chemotherapy agent tegafur. Drug Dev Ind Pharm. 2010 Jun;36(6):744-50. PubMed PMID: 20345283.

4: Naito S, Tsukamoto T, Usami M, Fujimoto H, Akaza H. An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2010 Feb 16. [Epub ahead of print] PubMed PMID: 20157711.

5: Liu K, Zhong D, Zou H, Chen X. Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2010 Aug 1;52(4):550-6. Epub 2010 Jan 21. PubMed PMID: 20138454.

6: Hatano H, Kobayashi S, Nagano H, Tomokuni A, Tomimaru Y, Murakami M, Marubashi S, Eguchi H, Takeda Y, Tanemura M, Wakasa K, Doki Y, Mori M. [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. Gan To Kagaku Ryoho. 2009 Nov;36(12):2374-6. Japanese. PubMed PMID: 20037427.

7: Ami K, Nagahama T, Ohara T, Ganno H, Hataji K, Kurokawa T, Fukuda A, Andou M, Tei S, Arai K. [A case of recurrence gastric cancer patient who was post operated and multi drug chemotherapy was effective for administration of S-1 and docetaxel combination therapy]. Gan To Kagaku Ryoho. 2009 Nov;36(12):2336-8. Japanese. PubMed PMID: 20037414.

8: Hataji K, Ami K, Nagahama T, Ohara T, Ganno H, Kawasaki N, Fukuda A, Ando M, Arai K, Tei S. [A case of unresectable cardiac gastric cancer patient who maintained a long-term QOL with chemotherapy and detention of metallic stent]. Gan To Kagaku Ryoho. 2009 Nov;36(12):2290-3. Japanese. PubMed PMID: 20037399.

9: Kadono K, Kawamoto K, Park T. [A case of cancer successfully treated by chemotherapy of S-1 as first-line chemotherapy]. Gan To Kagaku Ryoho. 2009 Dec;36(13):2661-3. Japanese. PubMed PMID: 20009476.

10: Ishii Y, Suzuki S, Takahashi Y, Takayama T, Asai S. Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1? Cancer Chemother Pharmacol. 2010 Jul;66(2):333-43. Epub 2009 Nov 18. PubMed PMID: 19921195.

11: Akasaka O, Iwase S, Miwa H, Ando T, Morita S, Koh R, Kasama M, Matsueda R, Anan H. [Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer]. Gan To Kagaku Ryoho. 2009 Nov;36(11):1833-7. Japanese. PubMed PMID: 19920384.

12: Abe K, Wakatsuki T, Katsushima F, Monoe K, Kanno Y, Takahashi A, Yokokawa J, Ohira H. A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy. World J Gastroenterol. 2009 Nov 7;15(41):5228-31. PubMed PMID: 19891026; PubMed Central PMCID: PMC2773906.

13: Yanagihara K, Tsumuraya M, Takigahira M, Mihara K, Kubo T, Ohuchi K, Seyama T. An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy. Int J Cancer. 2010 Jun 15;126(12):2835-46. PubMed PMID: 19876922.

14: Suzuki S, Ishikawa K. Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer. J Infect Chemother. 2009 Oct;15(5):335-9. Epub 2009 Oct 24. PubMed PMID: 19856075.

15: Kanbe T, Kishimoto Y, Tsunoda H, Imamoto R, Mukouyama T, Nishimuki E, Shabana M, Kojo H. [Effectiveness of S-1 therapy for unresectable/advanced pancreas cancer]. Gan To Kagaku Ryoho. 2009 Sep;36(9):1475-80. Japanese. PubMed PMID: 19755815.

16: Taguchi T, Noguchi S. [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer]. Gan To Kagaku Ryoho. 2009 Sep;36(9):1465-74. Japanese. PubMed PMID: 19755814.

17: Igarashi T, Saikawa Y, Kumagai K, Nakamura R, Takahashi T, Takeuchi Y, Kitagawa Y. [Report of a case successfully treated with chemo-radiation against local recurrence after gastric cancer surgery]. Gan To Kagaku Ryoho. 2009 Aug;36(8):1363-6. Japanese. PubMed PMID: 19692780.

18: Kataoka H, Shimura T, Mizoshita T, Kubota E, Mori Y, Mizushima T, Wada T, Ogasawara N, Tanida S, Sasaki M, Togawa S, Sano H, Hirata Y, Ikai M, Mochizuki H, Seno K, Itoh S, Kawai T, Joh T. Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life. Hepatogastroenterology. 2009 Mar-Apr;56(90):547-50. PubMed PMID: 19579640.

19: Harada K, Ferdous T, Itashiki Y, Takii M, Mano T, Mori Y, Ueyama Y. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Anticancer Res. 2009 Apr;29(4):1263-70. PubMed PMID: 19414373.

20: Fujita K, Nakayama H, Ichikawa W, Yamamoto W, Endo H, Nagashima F, Tanaka R, Miya T, Sunakawa Y, Yamashita K, Mizuno K, Ishida H, Araki K, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Hirose T, Sasaki Y. Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine). Drug Metab Dispos. 2009 Jul;37(7):1375-7. Epub 2009 Apr 23. PubMed PMID: 19389859.

21: Nishikawa K, Iwase K, Fujii M, Matsuda C, Shimada K, Hirota M, Kimura T, Wada D, Nasu S, Tanaka Y. [Administration of S-1 after gastrojejunostomy for unresectable gastric cancer with pyloric stenosis]. Gan To Kagaku Ryoho. 2009 Apr;36(4):595-8. Japanese. PubMed PMID: 19381030.

22: Totani Y, Saito Y, Hayashi M, Tada T, Kohashi Y, Mieno Y, Kato A, Imizu H, Yoneda Y, Hoshino T, Uchiyama Y, Takeuchi Y, Okazawa M, Sakakibara H. A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2009 Nov;64(6):1181-5. Epub 2009 Apr 18. PubMed PMID: 19377885.

23: Yamashita T, Shinden S, Watabe T, Shiotani A. Outpatient chemotherapy with S-1 for recurrent head and neck cancer. Anticancer Res. 2009 Feb;29(2):577-81. PubMed PMID: 19331206.

24: Ohba T, Yamasaki T, Endo Y, Furuie M, Ohtani Y, Inase N, Yoshizawa Y. A phase I study of TS-1 plus carboplatin in patients with advanced non-small-cell lung cancer. J Chemother. 2009 Feb;21(1):80-5. PubMed PMID: 19297278.

25: Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009 Mar;18(3):335-48. Review. PubMed PMID: 19243284.

26: Suzuki S, Hanata K, Nanjo H, Ishikawa K. Adenosquamous carcinoma of maxillary sinus: case showing complete response to S-1. J Laryngol Otol. 2009 Nov;123(11):1271-5. Epub 2009 Jan 20. PubMed PMID: 19152726.

27: Tanaka Y, Kurokawa T, Arita K, Kuramochi J, Usui S, Matsumoto A, Takiguchi N, Hiranuma S, Sanada K. [A case of recurrent breast carcinoma metastasis successfully treated with S-1 and zoledronic acid therapy]. Gan To Kagaku Ryoho. 2009 Jan;36(1):97-9. Japanese. PubMed PMID: 19151571.

28: Fujita K, Ichikawa W, Yamamoto W, Endo H, Nagashima F, Tanaka R, Miya T, Araki K, Kodama K, Sunakawa Y, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Sasaki Y. Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas. Ann Oncol. 2009 May;20(5):946-9. Epub 2009 Jan 15. PubMed PMID: 19150953.

29: Mitsuoka S, Onoda T, Tabuchi Y, Harafuji I. [A case of advanced gastric cancer successfully treated by S-1 based chemotherapy]. Gan To Kagaku Ryoho. 2008 Dec;35(13):2401-4. Japanese. PubMed PMID: 19098411.

30: Kitajima K, Kobayashi S, Shiba H, Uwagawa T, Ishida Y, Aiba K, Kawakami M, Yanaga K. Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene. Int J Clin Oncol. 2008 Dec;13(6):545-51. Epub 2008 Dec 18. PubMed PMID: 19093184.

31: Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009 Jan;39(1):2-15. Epub 2008 Dec 3. PubMed PMID: 19052037; PubMed Central PMCID: PMC2639406.

32: Ohashi M, Kanda T, Hirota M, Kobayashi T, Yajima K, Kosugi S, Hatakeyama K. Gastrojejunostomy as induction treatment for S-1-based chemotherapy in patients with incurable gastric cancer. Surg Today. 2008;38(12):1102-7. Epub 2008 Nov 28. PubMed PMID: 19039635.

33: Takashima T, Nakata B, Hatama M, Nomura S, Komoto M, Ishikawa T, Hirakawa K. Gastric cancer with cervical lymph node metastasis as the first presentation: report of a case. Int Surg. 2008 Sep-Oct;93(5):295-9. PubMed PMID: 19943433.

34: Uka K, Aikata H, Mori N, Takaki S, Kawakami Y, Azakami T, Kawaoka T, Jeong SC, Takahashi S, Chayama K. Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology. 2008;75(1-2):8-16. Epub 2008 Aug 22. PubMed PMID: 18719349.

35: Tanabe D, Kondou K, Uchiyama T, Noda K. [A case of scirrhous gastric cancer with peritoneal dissemination acquiring stable disease over three years by treatment with oral anticancer drug S-1]. Gan To Kagaku Ryoho. 2008 Aug;35(8):1391-3. Japanese. PubMed PMID: 18701856.

36: Pozzo C, Barone C. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist. 2008 Jul;13(7):794-806. Epub 2008 Jul 9. PubMed PMID: 18614586.

37: Sakurai Y, Yoshida I, Kamoshida S, Inaba K, Isogaki J, Komori Y, Uyama I, Tsutsumi Y. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts. Ann Surg Oncol. 2008 Aug;15(8):2301-9. Epub 2008 May 28. PubMed PMID: 18506536.

38: Tsujimoto S, Fujimoto K, Okajima E, Ozono S, Okajima E, Hirao Y. 5-Fluorouracil incorporated into the tissue RNA of human and rat bladder carcinoma after administration of 1-(2-tetrahydrofuryl)-5-fluorouracil combined with uracil. Int J Clin Oncol. 2008 Apr;13(2):138-43. Epub 2008 May 8. PubMed PMID: 18463958.

39: Okamoto I. Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol. 2008 Apr;13(2):112-6. Epub 2008 May 8. Review. PubMed PMID: 18463953.

40: Yoshimatsu K, Yokomizo H, Fujimoto T, Otani T, Matsumoto A, Osawa G, Itagaki H, Umehara A, Shiozawa S, Katsube T, Naritaka Y, Ogawa K. Successful treatment with S-1 plus CPT-11 for lymph node metastasis from colon cancer: report of a case. Anticancer Res. 2008 Jan-Feb;28(1B):559-62. PubMed PMID: 18383902.

41: Yoshimatsu K, Kuhara K, Itagaki H, Aizawa M, Yokomizo H, Fujimoto T, Otani T, Osawa G, Kobayashi R, Ogawa K. Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer. Anticancer Res. 2008 Jan-Feb;28(1B):373-8. PubMed PMID: 18383872.

42: Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, Tanaka R, Miya T, Araki K, Kodama K, Sunakawa Y, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Kamataki T, Sasaki Y. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci. 2008 May;99(5):1049-54. PubMed PMID: 18380793.

43: Yano S, Kizaki J, Imaizumi T, Koga A, Miyagi M, Shirouzu K. [Therapeutic experience of S-1 plus other drug combination therapy for synchronia multiple liver metastases of gastric cancer]. Gan To Kagaku Ryoho. 2008 Mar;35(3):445-9. Japanese. PubMed PMID: 18347394.

44: Nakajo A, Hokita S, Ishigami S, Miyazono F, Etoh T, Hamanoue M, Maenohara S, Iwashita T, Komatsu H, Satoh K, Aridome K, Morita S, Natsugoe S, Takiuchi H, Nakano S, Maehara Y, Sakamoto J, Aikou T; Kyushu Taxol TS-1 Study Group. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer. Cancer Chemother Pharmacol. 2008 Nov;62(6):1103-9. Epub 2008 Mar 4. PubMed PMID: 18317763.

45: Shien T, Shimizu C, Akashi-Tanaka S, Yonemori K, Kohno T, Hojo T, Ando M, Katsumata N, Kinoshita T, Fujiwara Y. Clinical efficacy of S-1 in pretreated metastatic breast cancer patients. Jpn J Clin Oncol. 2008 Mar;38(3):172-5. Epub 2008 Feb 22. PubMed PMID: 18296424.

46: Ishikawa T, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Takeda K, Kamimura T. Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer. Hepatogastroenterology. 2007 Dec;54(80):2378-82. PubMed PMID: 18265669.

47: Emi Y, Sumiyoshi Y, Oki E, Kakeji Y, Fukui Y, Maehara Y. Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer. Fukuoka Igaku Zasshi. 2007 Dec;98(12):418-24. PubMed PMID: 18260367.

48: Arias JL, Linares-Molinero F, Gallardo V, Delgado AV. Study of carbonyl iron/poly(butylcyanoacrylate) (core/shell) particles as anticancer drug delivery systems Loading and release properties. Eur J Pharm Sci. 2008 Mar 3;33(3):252-61. Epub 2007 Dec 23. PubMed PMID: 18249100.

49: Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer. 2008 Feb 26;98(4):832-9. Epub 2008 Jan 29. PubMed PMID: 18231104; PubMed Central PMCID: PMC2259181.

50: Watanabe F, Iwasaki Y, Ohashi M, Nunobe S, Iwagami S, Takahashi K, Yamaguchi T, Matsumoto H, Yasutome M. [A case report-the marked response to S-1 + CDDP chemotherapy for post-operative local recurrence of advanced gastric cancer]. Gan To Kagaku Ryoho. 2007 Nov;34(12):1970-2. Japanese. PubMed PMID: 18219868.

51: Kaida Y, Inui N, Suda T, Nakamura H, Watanabe H, Chida K. The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. Clin Pharmacol Ther. 2008 Apr;83(4):589-94. Epub 2008 Jan 23. PubMed PMID: 18212800.

52: Engel D, Nudelman A, Tarasenko N, Levovich I, Makarovsky I, Sochotnikov S, Tarasenko I, Rephaeli A. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties. J Med Chem. 2008 Jan 24;51(2):314-23. Epub 2007 Dec 29. PubMed PMID: 18163551.

53: Harada K, Sato M, Ueyama Y, Nagayama M, Hamakawa H, Nagahata S, Yoshimura Y, Osaki T, Ryoke K; Oral Cancer Study Group of Chugoku-Shikoku. Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Anticancer Drugs. 2008 Jan;19(1):85-90. PubMed PMID: 18043133.

54: Nakamura R, Saikawa Y, Wada N, Yoshida M, Kubota T, Kumai K, Kitajima M, Kitagawa Y. [Retrospective analysis of treatment for advanced gastric cancer with peritoneal dissemination]. Gan To Kagaku Ryoho. 2007 Nov;34(11):1827-31. Japanese. PubMed PMID: 18030017.

55: Isogai A, Nagaya M, Matsuoka H, Watanabe T, Tsukikawa S, Kubota S. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer. Surgery. 2007 Nov;142(5):741-8. PubMed PMID: 17981195.

56: Tanaka F. UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. Surg Today. 2007;37(11):923-43. Epub 2007 Oct 25. Review. PubMed PMID: 17952521.

57: Arias JL, Ruiz MA, Gallardo V, Delgado AV. Tegafur loading and release properties of magnetite/poly(alkylcyanoacrylate) (core/shell) nanoparticles. J Control Release. 2008 Jan 4;125(1):50-8. Epub 2007 Sep 26. PubMed PMID: 17949844.

58: Furuse J, Nakachi K, Suzuki E, Shimizu S, Ishii H, Yoshino M. [Unresectable gallbladder cancer with lymph node and liver metastases completely responding to S-1 monotherapy - a case report]. Gan To Kagaku Ryoho. 2007 Oct;34(10):1679-82. Japanese. PubMed PMID: 17940390.

59: Vormittag L, Kornek GV, Gruhsmann B, Lenauer A, Föger A, Depisch D, Lang F, Scheithauer W. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis. Anticancer Drugs. 2007 Jul;18(6):709-12. PubMed PMID: 17762401.

60: Itashiki Y, Harada K, Ferdous T, Yoshida H. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Anticancer Res. 2007 Jul-Aug;27(4B):2365-75. PubMed PMID: 17695527.

61: Amano A, Ohkawa S, Ueno M. [A case report of S-1 monotherapy as first-line treatment for metastatic gallbladder cancer]. Gan To Kagaku Ryoho. 2007 Aug;34(8):1307-9. Japanese. PubMed PMID: 17687220.

62: Urata Y, Negoro S, Satouchi M, Kurata T, Yoshimura S, Shimada T, Takada Y. Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug. Med Oncol. 2007;24(1):103-7. PubMed PMID: 17673819.

63: Sun BG, Chen ZX, Zhang SJ, Liu YD, Huang HZ, Yin LR. [Expression of PTEN in athymic mice with HCC treated by complex prescription of Chinese crude drug]. Zhongguo Zhong Yao Za Zhi. 2007 Jun;32(11):1057-60. Chinese. PubMed PMID: 17672343.

64: Selvaggi G, Scagliotti GV. Perspectives in adjuvant chemotherapy in NSCLC. Expert Rev Respir Med. 2007 Aug;1(1):99-110. PubMed PMID: 20477270.

65: Yoshimatsu K, Yokomizo H, Fujimoto T, Umehara A, Otani T, Matsumoto A, Osawa G, Ogawa K. Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer. Anticancer Res. 2007 May-Jun;27(3B):1657-61. PubMed PMID: 17595792.

66: Nio Y, Toga T, Maruyama R, Fukushima M. Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy. Oncol Rep. 2007 Jul;18(1):59-64. PubMed PMID: 17549346.

67: Shinchi H, Maemura K, Noma H, Mataki Y, Aikou T, Takao S. Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. Br J Cancer. 2007 May 7;96(9):1353-7. Epub 2007 Apr 17. PubMed PMID: 17437021; PubMed Central PMCID: PMC2360168.

68: Kobayashi R, Yoshimatsu K, Yokomizo H, Katsube T, Ogawa K. Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity. Anticancer Res. 2007 Jan-Feb;27(1B):675-9. PubMed PMID: 17348459.

69: Arias JL, Gallardo V, Ruiz MA, Delgado AV. Ftorafur loading and controlled release from poly(ethyl-2-cyanoacrylate) and poly(butylcyanoacrylate) nanospheres. Int J Pharm. 2007 Jun 7;337(1-2):282-90. Epub 2006 Dec 23. PubMed PMID: 17223292.

70: Katsumata K, Mori Y, Hisada M, Ishizaki T, Suzuki S, Wada T, Tsuchida A, Aoki T. [CR of rectal cancer and synchronous liver and lung metastases obtained with TS-1 plus CPT-11 combination therapy--case report]. Gan To Kagaku Ryoho. 2007 Jan;34(1):113-5. Japanese. PubMed PMID: 17220684.

71: González-Díaz H, Bonet I, Terán C, De Clercq E, Bello R, García MM, Santana L, Uriarte E. ANN-QSAR model for selection of anticancer leads from structurally heterogeneous series of compounds. Eur J Med Chem. 2007 May;42(5):580-5. Epub 2006 Dec 15. PubMed PMID: 17207560.

72: Ito S, Tanaka A. [Three cases of corneal disorders associated with an oral anticancer drug S-1]. Nippon Ganka Gakkai Zasshi. 2006 Nov;110(11):919-23. Japanese. PubMed PMID: 17134039.

73: Oguro A, Nanri M, Miyamoto Y, Ujiie K, Iitaka D, Suzuki T, Koh T, Kobayashi S, Yamazaki J. [Partial response of liver metastasis from colon cancer following intermittent oral administration of TS-1 after intra-hepatic arterial single injection of CDDP, doxorubicin and 5-FU]. Gan To Kagaku Ryoho. 2006 Nov;33(11):1669-71. Japanese. PubMed PMID: 17108740.

74: Ikeda M, Ueno H. [Two patients effectively treated by S-1 monotherapy for metastatic pancreatic cancer]. Gan To Kagaku Ryoho. 2006 Oct;33(10):1515-9. Japanese. PubMed PMID: 17033250.

75: Mizuno N, Sawaki A, Yamao K. [Resolution of liver metastases in response to S-1 monotherapy in advanced pancreatic cancer--a case report]. Gan To Kagaku Ryoho. 2006 Oct;33(10):1511-4. Japanese. PubMed PMID: 17033249.

76: Kawasaki M, Watanabe K, Watanabe J. [TS-1 and irradiation combination therapy for head and neck cancer]. Gan To Kagaku Ryoho. 2006 Aug;33(8):1077-80. Japanese. PubMed PMID: 16912525.

77: Nakamura K, Yamaguchi T, Sudo K, Ishihara T, Saisho H. [Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer]. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:219-23. Japanese. PubMed PMID: 16898006.

78: Yumine K, Kawahara M. [Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer]. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:189-92. Japanese. PubMed PMID: 16898000.

79: Saikawa Y, Kiyota T, Nakamura R, Wada N, Yoshida M, Kubota T, Kumai K, Shigematsu N, Kubo A, Kitajima M. [A recent trial of chemo-radiation with S-1 against gastric cancer]. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:99-105. Review. Japanese. PubMed PMID: 16897982.

80: Fukushima M. [Antitumor activity and function of S-1, a new oral tegafur-based formulation]. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:19-26. Japanese. PubMed PMID: 16897968.

81: Shirasaka T, Taguchi T. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept]. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:4-18. Review. Japanese. PubMed PMID: 16897967.

82: Mori S, Kishimoto H, Tauchi K, Higuchi K. Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy. Gastric Cancer. 2006;9(2):136-9. PubMed PMID: 16767370.

83: Ooyama A, Takechi T, Toda E, Nagase H, Okayama Y, Kitazato K, Sugimoto Y, Oka T, Fukushima M. Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. Erratum in: Cancer Sci. 2006 Aug;97(8):799. PubMed PMID: 16734730.

84: Sakurai Y, Sakamoto K, Sugimoto Y, Yoshida I, Masui T, Tonomura S, Inaba K, Shoji M, Nakamura Y, Uyama I, Komori Y, Ochiai M, Matsuura S, Tanaka H, Oka T, Fukushima M. Orotate phosphoribosyltransferase levels measured by a newly established enzyme-linked immunosorbent assay in gastric carcinoma. Cancer Sci. 2006 Jun;97(6):492-8. PubMed PMID: 16734727.

85: Miyake K, Tsuchida K, Sugino H, Imura S, Morine Y, Fujii M, Shimada M. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha. Cancer Chemother Pharmacol. 2007 Jan;59(1):113-26. Epub 2006 May 13. PubMed PMID: 16699793.

86: Uyama R, Yoshizawa Y, Tajiri T, Endo Y, Mitsuya T, Sanada Y. [Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients]. Gan To Kagaku Ryoho. 2006 May;33(5):625-9. Japanese. PubMed PMID: 16685161.

87: Kawabata R, Koida M, Kanie S, Tanaka G, Ohuchida A, Yoshida T. [DLST as a method for detecting TS-1-induced allergy]. Gan To Kagaku Ryoho. 2006 Mar;33(3):345-8. Japanese. PubMed PMID: 16531715.

88: Mado K, Ishii Y, Mazaki T, Ushio M, Masuda H, Takayama T. A case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resection. World J Surg Oncol. 2006 Jan 18;4:3. PubMed PMID: 16417646; PubMed Central PMCID: PMC1395313.

89: Sato N, Sano M. [Successful monotherapy with S-1 in three cases of recurrent/advanced breast cancer non-responsive to anthracycline and taxane anticancer drugs]. Gan To Kagaku Ryoho. 2006 Jan;33(1):137-40. Japanese. PubMed PMID: 16410715.

90: Sato Y. [Two patients effectively treated with S-1 therapy for liver metastasis of breast cancer resistant to other anticancer drugs]. Gan To Kagaku Ryoho. 2006 Jan;33(1):133-6. Japanese. PubMed PMID: 16410714.

91: Nishihara K, Mitsuyama S. [A case of liver metastasis successfully treated with S-1 monotherapy in the patient with recurrent breast cancer]. Gan To Kagaku Ryoho. 2006 Jan;33(1):129-32. Japanese. PubMed PMID: 16410713.

92: Kanazawa S, Seo A, Tokura N, Honda R, Kase H, Teramoto T. [Liver metastasis from sigmoid colon cancer with peritoneal dissemination showed a complete response to TS-1]. Gan To Kagaku Ryoho. 2006 Jan;33(1):113-7. Japanese. PubMed PMID: 16410710.

93: Shikano T, Koshikawa K, Kiriyama K, Wada M, Taniguchi K, Suenaga H. [Two cases of advanced gastric cancer with peritoneal dissemination acquired long-term response three years or more by postoperative treatment with oral anticancer drug TS-1]. Gan To Kagaku Ryoho. 2006 Jan;33(1):87-90. Japanese. PubMed PMID: 16410704.

94: Itoh K, Minami H. [Effective salvage chemotherapy with S-1 alone in a patient with lung metastasis of breast cancer]. Gan To Kagaku Ryoho. 2005 Dec;32(13):2141-3. Japanese. PubMed PMID: 16352946.

95: van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs. 2005 Dec;23(6):513-22. Review. PubMed PMID: 16267627.

96: Peng T, Cheng SX, Zhuo RX. Synthesis and characterization of poly-alpha,beta-[N-(2-hydroxyethyl)-L-aspartamide]-g-poly(L-lactide) biodegradable copolymers as drug carriers. J Biomed Mater Res A. 2006 Jan;76(1):163-73. PubMed PMID: 16258962.

97: Yamada K, Sugiyama Y, Seino K, Kobori H, Ebina T, Shibata S, Kawasaki H, Sasaki M, Tanaka M. [A Case of advanced gastric cancer successfully treated with TS-1/low-dose CDDP as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho. 2005 Oct;32(10):1447-51. Japanese. PubMed PMID: 16227746.

98: Seshimo A, Mitsuhashi M, Aratake K, Ogawa S, Itabashi M, Shirotani N, Kameoka S. [Prediction and treatment of peritoneal dissemination in gastric cancer]. Gan To Kagaku Ryoho. 2005 Oct;32(10):1393-7. Japanese. PubMed PMID: 16227736.

99: Koufuji K, Aoyagi K, Yano S, Murakami N, Miyagi M, Imaizumi T, Shirouzu K. [Peritoneal dissemination of scirrhous type 4 gastric cancers]. Gan To Kagaku Ryoho. 2005 Oct;32(10):1384-8. Japanese. PubMed PMID: 16227734.

100: Hamuro J. [Anticancer immunotherapy with perorally effective lentinan]. Gan To Kagaku Ryoho. 2005 Aug;32(8):1209-15. Review. Japanese. PubMed PMID: 16121931.

101: Miyake H, Hara I, Yamazaki H, Eto H. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer. Oncol Rep. 2005 Sep;14(3):673-6. PubMed PMID: 16077973.

102: Remaud G, Boisdron-Celle M, Morel A, Gamelin A. Sensitive MS/MS-liquid chromatography assay for simultaneous determination of tegafur, 5-fluorouracil and 5-fluorodihydrouracil in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 25;824(1-2):153-60. PubMed PMID: 16061432.

103: Takashima T, Nakata B, Komoto M, Nomura S, Sawada T, Ohira M, Ishikawa T, Hirakawa K. [A case of gastric cancer with peritoneal recurrence which developed during adjuvant administration of TS-1 showing complete response by weekly docetaxel regimen]. Gan To Kagaku Ryoho. 2005 Jul;32(7):1041-4. Japanese. PubMed PMID: 16044970.

104: Yoshida I, Sakurai Y, Komori Y, Tonomura S, Masui T, Shoji M, Nakamura Y, Imazu H, Uyama I, Ochiai M. Successful downstaging by S-1-based chemotherapy followed by surgical resections for gastric carcinoma with extensive distant lymph node metastasis - report of two cases and a review of cases with surgical resection after downstaging by S-1-based chemotherapy. Hepatogastroenterology. 2005 May-Jun;52(63):978-84. PubMed PMID: 15966245.

105: Nagashima F, Ohtsu A, Yoshida S, Ito K. Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer. 2005;8(1):6-11. PubMed PMID: 15747168.

106: Gupta S, Mauer AM, Ryan CW, Taber DA, Samuels BL, Fleming GF; University of Chicago Phase II Network. A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. Am J Clin Oncol. 2005 Feb;28(1):65-9. PubMed PMID: 15685037.

107: Woo IS, Moon DH, Shim BY, Lee MA, Byun JH, Kim KW, Kang JH, Choi MG, Chung IS, Hong YS, Park SY, Lee KS. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. Jpn J Clin Oncol. 2005 Jan;35(1):13-7. PubMed PMID: 15681598.

108: Itakura J, Izumi N, Inoue K, Nishimura M, Ueda K, Tsuchiya K, Hamano K, Asahina Y, Noguchi O, Uchihara M, Miyake S. [A case of advanced gastric cancer acquired long-term response two years or more by treatment with oral anticancer drug TS-1]. Gan To Kagaku Ryoho. 2004 Dec;31(13):2169-71. Japanese. PubMed PMID: 15628765.

109: Mushiake H, Tsunoda T, Nukatsuka M, Shimao K, Fukushima M, Tahara H. Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo. Cancer Immunol Immunother. 2005 Feb;54(2):120-8. Epub 2004 Sep 22. PubMed PMID: 15592717.

110: Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 2004 Dec 1;10(23):7860-4. PubMed PMID: 15585618.

111: Emi Y, Kakeji Y, Baba H, Ishida T, Maehara Y. [Current combination chemotherapy containing paclitaxel for advanced, recurrent gastric cancer]. Gan To Kagaku Ryoho. 2004 Nov;31(12):1978-81. Review. Japanese. PubMed PMID: 15570924.

112: Nukatsuka M, Fujioka A, Nakagawa F, Oshimo H, Kitazato K, Uchida J, Sugimoto Y, Nagayama S, Fukushima M. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. Int J Oncol. 2004 Dec;25(6):1531-6. PubMed PMID: 15547687.

113: Yamagata S, Nakata B, Hirakawa K. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer. Oncol Rep. 2004 Nov;12(5):973-8. PubMed PMID: 15492780.

114: Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H, Sato M. Enhancement of apoptosis in salivary gland cancer cells by the combination of oral fluoropyrimidine anticancer agent (S-1) and radiation. Int J Oncol. 2004 Oct;25(4):905-11. PubMed PMID: 15375539.

115: Rustum YM. Thymidylate synthase: a critical target in cancer therapy? Front Biosci. 2004 Sep 1;9:2467-73. Review. PubMed PMID: 15353299.

116: Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res. 2004 Aug 1;10(15):4913-21. PubMed PMID: 15297391.

117: Wang J, Yang M, Yagi S, Hoffman RM. Oral 5-FU is a more effective antimetastatic agent than UFT. Anticancer Res. 2004 May-Jun;24(3a):1353-60. PubMed PMID: 15274295.

118: Takashima T, Kashiwagi K, Sasaki K, Inoue D, Maeda H, Shibuya H, Hirata K. [A case of advanced gastric cancer with bulky N2 lymph node metastases resected after successful treatment with TS-1]. Gan To Kagaku Ryoho. 2004 Jun;31(6):935-7. Japanese. PubMed PMID: 15222116.

119: Mimatsu K, Oida T, Kuboi Y, Kawasaki A, Kanou H, Kaneda H, Amano S. A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy. Int J Clin Oncol. 2004 Jun;9(3):193-6. PubMed PMID: 15221605.

120: Arai W, Hosoya Y, Hyodo M, Yokoyama T, Hirashima Y, Yasuda Y, Nagai H, Shirasaka T. Alternate-day oral therapy with TS-1 for advanced gastric cancer. Int J Clin Oncol. 2004 Jun;9(3):143-8. PubMed PMID: 15221596.

121: Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H, Sato M. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol. 2004 Aug;40(7):713-9. PubMed PMID: 15172641.

122: Kireev GV, Navruzov SN, Iusupova AA, Akhunov AA, Ibragimov FA, Sadykov AA. [Experimental investigation of the anticancer effects of soy proteins]. Vopr Onkol. 2004;50(1):101-2. Russian. PubMed PMID: 15088532.

123: Schöffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs. 2004 Feb;15(2):85-106. Review. PubMed PMID: 15075664.

124: Yagyu T, Aihara T, Murayama M, Nakamura E, Nozaki H, Niida M, Yasuoka H, Nishimoto Y, Watanabe Y, Syouda S, Kouno T, Fukuhara A, Nakagawa K. [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11]. Gan To Kagaku Ryoho. 2004 Mar;31(3):431-3. Japanese. PubMed PMID: 15045956.

125: Takashima T, Yamagata S, Fukunaga S, Inoue T, Yashiro M, Nakata B, Nishiguchi Y, Kato Y, Ohira M, Ishikawa T, Hirakawa K. [A case of gastric cancer with umbilical metastasis that responded to TS-1 with low-dose cis-platinum]. Gan To Kagaku Ryoho. 2004 Feb;31(2):247-50. Japanese. PubMed PMID: 14997761.

126: Tokumitsu Y, Nagano C, Matsuura T, Seo M, Mitsugi K. [A case of malignant gastric outlet stenosis palliated with self-expandable metallic stent and responding to TS-1, an oral fluorouracil derivative]. Gan To Kagaku Ryoho. 2004 Jan;31(1):99-102. Japanese. PubMed PMID: 14750331.

127: Cats A. New developments in systemic chemotherapy in advanced colorectal cancer. Scand J Gastroenterol Suppl. 2003;(239):78-86. Review. PubMed PMID: 14743888.

128: Morimoto S, Shono Y, Tsuji T, Makihara K, Kawato N, Hachino Y, Mishima H, Tsujinaka T, Tabuse K. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance]. Gan To Kagaku Ryoho. 2003 Dec;30(13):2083-9. Japanese. PubMed PMID: 14712769.

129: Suzuki S, Yoshihara T. [A case of lymph node metastasis after total laryngectomy successfully treated with chemoradiotherapy with TS-1]. Gan To Kagaku Ryoho. 2003 Nov;30(12):1945-7. Japanese. PubMed PMID: 14650964.

130: Baba H, Kakeji Y, Oki E, Tokunaga E, Ushiro S, Watanabe M, Maehara Y. [Chemotherapy for gastric cancer]. Gan To Kagaku Ryoho. 2003 Nov;30(12):1881-8. Review. Japanese. PubMed PMID: 14650954.

131: Comets E, Ikeda K, Hoff P, Fumoleau P, Wanders J, Tanigawara Y. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J Pharmacokinet Pharmacodyn. 2003 Aug;30(4):257-83. PubMed PMID: 14650374; PubMed Central PMCID: PMC2100153.

132: Nakao K, Fujiwara Y, Koishi K, Nishizaki K, Nakagawa K, Ooiwa N, Yamamura T. [A case of distant metastasis from advanced gastric cancer treated with TS-1, which maintained NC (no change) for 9 months]. Gan To Kagaku Ryoho. 2003 Oct;30(10):1505-9. Japanese. PubMed PMID: 14584286.

133: Mikami Y, Tsukuda M, Kawai S, Kagesato Y, Tanigaki Y, Horiuchi C, Mochimatsu I. [Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1]. Gan To Kagaku Ryoho. 2003 Oct;30(10):1473-7. Japanese. PubMed PMID: 14584280.

134: Yoshimizu N, Saikawa Y, Kubota T, Akiba Y, Yoshida M, Otani Y, Kumai K, Hibi T, Kitajima M. Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin. Gastric Cancer. 2003;6(3):185-90. PubMed PMID: 14520533.

135: Arai K, Iwasaki Y, Kimura Y, Takahashi K, Yamaguchi T, Honma S, Takahashi T. [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients]. Gan To Kagaku Ryoho. 2003 Sep;30(9):1297-301. Japanese. PubMed PMID: 14518409.

136: Nimura H, Mitsumori N, Tsukagoshi S, Nakajima M, Atomi Y, Suzuki S, Kusano M, Yoshiyuki T, Tokunaga A. [Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer]. Gan To Kagaku Ryoho. 2003 Sep;30(9):1289-96. Japanese. PubMed PMID: 14518408.

137: Ishikawa T, Nomura K, Baba Y, Hayashi S, Oota H, Yoshida T, Kamimura T. [A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy]. Gan To Kagaku Ryoho. 2003 Aug;30(8):1151-5. Japanese. PubMed PMID: 12938272.

138: Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol. 2003 Jun;8(3):132-8. Review. PubMed PMID: 12851836.

139: El-Masry EM, Abou-Donia MB. Reversal of P-glycoprotein expressed in Escherichia coli leaky mutant by ascorbic acid. Life Sci. 2003 Jul 11;73(8):981-91. PubMed PMID: 12818351.

140: Tsujitani S, Fukuda K, Kaibara N. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer. Gastric Cancer. 2003;6 Suppl 1:50-7. PubMed PMID: 12775021.

141: Kimura Y, Kikkawa N, Iijima S, Kato T, Naoi Y, Hayashi T, Tanigawa T, Yamamoto H, Kurokawa E. A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer. 2003;6 Suppl 1:34-9. PubMed PMID: 12775018.

142: Takahashi I, Kakeji Y, Emi Y, Sakurai M, Yonemura Y, Kimura Y, Maehara Y. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects. Gastric Cancer. 2003;6 Suppl 1:28-33. PubMed PMID: 12775017.

143: Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S, Monden M. Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer. Gastric Cancer. 2003;6 Suppl 1:13-8. PubMed PMID: 12775014.

144: Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer. 2003;6 Suppl 1:2-8. Review. PubMed PMID: 12775012.

145: Urien S, Fumoleau P, Campone M, Kerbrat P, Bonneterre J, Fargeot P, Deporte-Fety R. Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Cancer Chemother Pharmacol. 2003 Aug;52(2):99-107. Epub 2003 May 27. PubMed PMID: 12768319.

146: Koyama M, Inaba Y, Watabe S, Hayashi K, Tsuge T, Kamio Y, Chiba M, Tamura M. [A case of advanced gastric cancer resected after successful treatment with the novel oral anticancer drug TS-1]. Gan To Kagaku Ryoho. 2003 Apr;30(4):531-5. Japanese. PubMed PMID: 12722688.

147: Tanaka N, Takeda M, Yoshioka H. [Combination therapy of fluoropyrimidine (TS-1) administration and selective intra-arterial cisplatin infusion for tongue carcinoma--a case report]. Gan To Kagaku Ryoho. 2003 Apr;30(4):511-4. Japanese. PubMed PMID: 12722683.

148: Omoto Y, Sekiguchi C, Hyodo M, Ohdaira T, Kumano H, Ohtuka S. [A case report of adjuvant chemotherapy (TS-1) for far advanced gastric cancer in which the patient maintained a good quality of life]. Gan To Kagaku Ryoho. 2003 Mar;30(3):399-402. Japanese. PubMed PMID: 12669400.

149: Kasumi F, Yoshimoto M, Uchino J, Abe R, Nomura Y, Sugimachi K, Nakazato H, Abe O. Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer. Oncology. 2003;64(2):146-53. PubMed PMID: 12566912.

150: Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res. 2003 Jan;9(1):134-42. PubMed PMID: 12538461.

151: Sato A, Shimada K, Nakamachi M, Ushio J, Yamamoto W, Kurihara M, Matsukawa M. Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens. Gastric Cancer. 2002;5(4):233-6. PubMed PMID: 12491082.

152: Kawasaki G, Yoshitomi I, Yanamoto S, Mizuno A. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Dec;94(6):717-23. PubMed PMID: 12464897.

153: Watanabe S, Tanaka T, Takeuchi T, Takabayashi H, Hirayama Y. Advanced gastric cancer with liver metastases successfully treated with S-1. Int J Clin Oncol. 2002 Oct;7(5):326-9. PubMed PMID: 12402069.

154: Korenaga D, Honda M, Yasuda M, Inutsuka S, Nozoe T, Tashiro H. Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats. Eur Surg Res. 2002 Sep-Oct;34(5):351-6. PubMed PMID: 12364819.

155: Iwase H, Shimada M, Nakamura M, Iyo T, Nakarai K, Kaida S, Indo T, Okeya M, Mizuno T, Ina K, Kusugami K. [A pilot study of TS-1 combined with cisplatin in patients with advanced gastric cancer]. Gan To Kagaku Ryoho. 2002 Sep;29(9):1575-82. Japanese. PubMed PMID: 12355943.

156: Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist. 2002;7(4):288-323. Review. PubMed PMID: 12185293.

157: Kubo S, Misawa T, Yoshida K, Nasu T, Ihara Y, Chinen T, Harada N, Nawada H. [Clinical study of individual TS-1 therapy for inoperable gastric cancer]. Gan To Kagaku Ryoho. 2002 Jul;29(7):1161-5. Japanese. PubMed PMID: 12145996.

158: Iwazawa T, Kinuta M, Yano H, Matsui S, Tamagaki S, Yasue A, Okada K, Kanoh T, Tono T, Nakano Y, Okamoto S, Monden T. An oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow's metastasis to receive curative resection. Gastric Cancer. 2002;5(2):96-101. PubMed PMID: 12111585.

159: Nakamura T, Yamasaki K, Morikawa S, Ohnita K, Taura K, Isomoto H, Mizuta Y, Murase K, Murata I, Kohno S. [A case report of advanced gastric cancer responding to TS-1, a novel oral fluorouracil derivative]. Gan To Kagaku Ryoho. 2002 Jun;29(6):927-32. Japanese. PubMed PMID: 12090046.

160: Osugi H, Takada N, Takemura M, Kaseno S, Lee S, Ueno M, Tanaka Y, Fukuhara K, Fujiwara Y, Kinoshita H. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination. Oncol Rep. 2002 Jul-Aug;9(4):811-5. PubMed PMID: 12066214.

161: Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W, Tanabe S, Saigenji K, Nagayama S, Ikeda K, Nishioka Y, Kamataki T. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics. 2002 Jun;12(4):299-306. PubMed PMID: 12042667.

162: Kobayashi O, Konishi K, Kanari M, Cho H, Yoshikawa T, Tsuburaya A, Sairenji M, Motohashi H. Unusual survival for more than 2 years with peritoneal metastases of gastric cancer. Gastric Cancer. 2002;5(1):47-50. PubMed PMID: 12021860.

163: Murata N, Idezuki Y, Konishi T, Watanabe H, Ushirokoji Y, Shinohara K, Shibusawa M, Haga S, Hiraishi M, Bandai Y, Yamamura T, Yumoto S, Gunji A, Nishigaki K. Influence of perioperative blood transfusion on the prognosis of patients with gastric cancer receiving anticancer chemotherapy. Gastric Cancer. 2000 Aug 4;3(1):24-27. PubMed PMID: 11984705.

164: Yokota M, Ouchi J, Miyagi Y, Matsuo S, Uchimura K, Sumii T, Iguchi H, Funakoshi A. [A case of advanced gastric cancer successfully treated with TS-1]. Gan To Kagaku Ryoho. 2002 Feb;29(2):293-5. Japanese. PubMed PMID: 11865636.

165: Inaba Y, Watabe S, Ohe S, Kamio Y, Koyama M, Hayashi K, Chiba M. [The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination]. Gan To Kagaku Ryoho. 2002 Feb;29(2):239-44. Japanese. PubMed PMID: 11865630.

166: Nagahama S, Korenaga D, Honda M, Inutsuka S, Sugimachi K. Assessment of the intestinal permeability after a gastrectomy and the oral administration of anticancer drugs in rats: nitric oxide release in response to gut injury. Surgery. 2002 Jan;131(1 Suppl):S92-7. PubMed PMID: 11821793.

167: Ishikura H, Kondo K, Miyoshi T, Kinoshita H, Takahashi Y, Fujino H, Monden Y. Suppression of mediastinal metastasis by uracil-tegafur or cis-diamminedichloroplatinum(II) using a lymphogenous metastatic model in a human lung cancer cell line. Clin Cancer Res. 2001 Dec;7(12):4202-8. PubMed PMID: 11751521.

168: Watanabe A, Yoriki R, Nakagawa M, Sado S, Yamada T, Kusumoto Y, Tamaki H, Hongo S. [A complete response persisting for twelve months with the use of TS-1 in a patient with paraaortic lymph node metastasis of gastric cancer]. Gan To Kagaku Ryoho. 2001 Nov;28(12):1913-6. Review. Japanese. PubMed PMID: 11729487.

169: Nishimura G, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Kayahara M, Shimizu K, Ohta T, Miwa K. [A case report of rectal cancer with liver and pulmonary metastases responding to TS-1]. Gan To Kagaku Ryoho. 2001 Oct;28(10):1453-6. Japanese. PubMed PMID: 11681257.

170: Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H; S-1 Cooperative Study Group (Lung Cancer Working Group). Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 2001 Sep 28;85(7):939-43. PubMed PMID: 11592762; PubMed Central PMCID: PMC2375091.

171: Iwatani Y, Shimada Y, Ohshima T, Kusunoki N, Yamazaki T, Miyazaki N. [Postoperative chemotherapy with a novel oral anticancer drug composed of tegafur, gimeracil and oteracil potassium to curability C scirrhus type gastric cancer]. Gan To Kagaku Ryoho. 2001 Aug;28(8):1129-32. Japanese. PubMed PMID: 11525030.

172: Iwahashi M, Nakamori M, Tani M, Yamaue H, Sakaguchi S, Nakamura M, Ueda K, Ichiro M, Nishino E, Tanimura H. Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case. Oncology. 2001;61(1):16-22. PubMed PMID: 11474243.

173: Kurakawa E, Kasuga I, Ishizuka S, Yoshida T, Kunisawa A, Minemura K, Utsumi K, Ohyashiki K. Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report. Jpn J Clin Oncol. 2001 Jun;31(6):284-6. PubMed PMID: 11463808.

174: Shirasaka T, Tsukuda M, Inuyama Y, Taguchi T. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic]. Gan To Kagaku Ryoho. 2001 Jun;28(6):855-64. Review. Japanese. PubMed PMID: 11432358.

175: Osako T, Okamura K, Inoue K, Taneda T, Tsuruzoe S, Fukuda S. [Three cases of advanced gastric cancer resected after successful treatment with the novel oral anticancer drug TS-1]. Gan To Kagaku Ryoho. 2001 May;28(5):677-83. Japanese. PubMed PMID: 11383217.

176: Ishikawa T, Ichida T, Sugitani S, Tsuboi Y, Genda T, Sugahara S, Uehara K, Inayoshi J, Yokoyama J, Ishimoto Y, Asakura H. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol. 2001 Apr;16(4):452-9. PubMed PMID: 11354285.

177: Yamazaki H, Komatsu T, Takemoto K, Shimada N, Nakajima M, Yokoi T. Rat cytochrome p450 1A and 3A enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes. Drug Metab Dispos. 2001 Jun;29(6):794-7. PubMed PMID: 11353746.

178: Onoda T, Okamura S, Takakura N, Shiozaki S, Ohno S, Higaki K, Ninomiya M, Ikeda T, Kobayashi N. [A case of recurrent gastric cancer successfully treated with TS-1]. Gan To Kagaku Ryoho. 2001 Apr;28(4):539-42. Japanese. PubMed PMID: 11329792.

179: Zurita Saavedra AJ, Navarro Garcia M, Español I, Fernández Ortega A. UFT-induced haemolytic anaemia. Cancer Chemother Pharmacol. 2001 Mar;47(3):280-1. PubMed PMID: 11320674.

180: Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res. 2001 Apr;7(4):1079-86. PubMed PMID: 11309360.

181: Komatsu T, Yamazaki H, Shimada N, Nagayama S, Kawaguchi Y, Nakajima M, Yokoi T. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver. Clin Cancer Res. 2001 Mar;7(3):675-81. PubMed PMID: 11297264.

182: Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, Hashimoto-Tamaoki T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 2001 Feb 1;61(3):1029-37. PubMed PMID: 11221829.

183: Omura K, Kawakami K, Kanehira E. [Theoretical construction of chemotherapeutic tactics for advanced or recurrent gastrointestinal carcinoma]. Gan To Kagaku Ryoho. 2001 Jan;28(1):63-8. Japanese. PubMed PMID: 11201382.

184: Sadahiro S, Ohki S, Yamaguchi S, Takahashi T, Otani Y, Tsukikawa S, Yamamura T, Takemiya S, Nagasaki H, Nishiyama K, Fukushima T, Hiki Y, Yamaguchi S, Kumada K, Shimada H, Mitomi T, Makuuchi H; UFT Compliance Study Group. [Optimal dosage of UFT in a weekday-on/weekend-off schedule as a postoperative adjuvant chemotherapy for colorectal cancer]. Gan To Kagaku Ryoho. 2000 Dec;27(14):2223-30. Japanese. PubMed PMID: 11142166.

185: Royce ME, Hoff PM, Pazdur R. Novel oral chemotherapy agents. Curr Oncol Rep. 2000 Jan;2(1):31-7. Review. PubMed PMID: 11122822.

186: Nagai N, Oshita T, Murakami J, Shigemasa K, Hirokawa Y, Ohama K. Radiotherapy combined with transcatheter arterial infusion of cisplatin versus oral fluoropyrimidine anticancer agent for locally advanced carcinoma of the uterine cervix: a prospective follow-up study. Oncol Rep. 2001 Jan-Feb;8(1):119-25. PubMed PMID: 11115582.

187: Takahashi Y, Tomita H, Yasuda K, Kawai M, Yamamori T, Furuichi N, Misawa K, Ohashi H. [A case report of TS-1 in a patient with advanced gastric cancer]. Gan To Kagaku Ryoho. 2000 Nov;27(13):2145-9. Japanese. PubMed PMID: 11103250.

188: Yamada Y, Miyagawa T, Toyoda H, Uesato K, Asanuma F, Ohsaku M, Kaneo K. [A complete response persisting for seven months with the use of TS-1 in a patient with paraaortic lymph node metastasis of gastric cancer]. Gan To Kagaku Ryoho. 2000 Nov;27(13):2139-43. Japanese. PubMed PMID: 11103249.

189: Shiota M, Shirai T, Tateyama I. [A patient with recurrent uterine cervical cancer successfully treated by combined modality therapy including local injection of anticancer agents based on CDDP]. Gan To Kagaku Ryoho. 2000 Nov;27(13):2117-21. Japanese. PubMed PMID: 11103245.

190: Nagano K, Fukuda Y, Nakano I, Katano Y, Toyoda H, Ebata M, Morita K, Yokozaki S, Takeuchi M, Hayashi K, Hayakawa T. An autopsy case of multilocular cystic hepatocellular carcinoma without liver cirrhosis. Hepatogastroenterology. 2000 Sep-Oct;47(35):1419-21. PubMed PMID: 11100365.

191: Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63. PubMed PMID: 11095583.

192: Shirasaka T, Yamamitsu S, Tsuji A, Taguchi T. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs. 2000 Nov;18(4):315-29. Review. PubMed PMID: 11081568.

193: Horikoshi N, Saotome T, Yoshida N, Aiba K. [Oral cancer chemotherapy in the clinic]. Gan To Kagaku Ryoho. 2000 Oct;27(11):1641-6. Review. Japanese. PubMed PMID: 11057313.

194: Sadahiro S, Ohki S, Yamaguchi S, Takahashi T, Otani Y, Tsukikawa S, Yamamura T, Takemiya S, Nagasaki H, Nishiyama K, Fukushima T, Hiki Y, Yamaguchi S, Kumada K, Shimada H, Mitomi T, Makuuchi H. Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. UFT Compliance Study Group, Kanagawa, Japan. Cancer Chemother Pharmacol. 2000;46(3):180-4. PubMed PMID: 11021734.

195: Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer. 2000 Jun 15;88(12 Suppl):2979-88. Review. PubMed PMID: 10898341.

196: Shirasaka T, Yamamitsu S, Tsuji A, Terashima M, Hirata K. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU]. Gan To Kagaku Ryoho. 2000 Jun;27(6):832-45. Review. Japanese. PubMed PMID: 10897209.

197: Shirasaka T. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic. Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:193-205. Review. PubMed PMID: 10895155.

198: Kitamura M, Arai K, Iwasaki Y, Takahashi T, Saitoh K, Fujii T, Shirasaka T. [Combined effect of S-1 and CDDP as a modulator for colon 26 liver metastasis]. Gan To Kagaku Ryoho. 2000 Apr;27(4):559-63. Japanese. PubMed PMID: 10790998.

199: Hoff PM, Lassere Y, Pazdur R. Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. Drugs. 1999;58 Suppl 3:77-83. Review. PubMed PMID: 10711845.

200: Kono T, Ishii M, Negoro N, Taniguchi S. Scleroderma-like reaction induced by uracil-tegafur (UFT), a second-generation anticancer agent. J Am Acad Dermatol. 2000 Mar;42(3):519-20. PubMed PMID: 10688731.

201: Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol. 1999 Dec;26(6):647-62. Review. PubMed PMID: 10606258.

202: Ignoffo RJ. Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer. Am J Health Syst Pharm. 1999 Dec 1;56(23):2417-28; quiz 2428-9. Review. PubMed PMID: 10595802.

203: Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology. 1999 Oct;57(3):202-10. PubMed PMID: 10545788.

204: Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999 Sep;5(9):2289-96. Review. PubMed PMID: 10499595.

205: Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Wierzba K, Yamada Y. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res. 1999 Aug;5(8):2185-91. PubMed PMID: 10473104.

206: Nakanishi H, Kobayashi K, Nishimura T, Inada K, Tsukamoto T, Tatematsu M. Chemosensitivity of micrometastases and circulating tumor cells to uracil and tegafur as evaluated using LacZ gene-tagged Lewis lung carcinoma cell. Cancer Lett. 1999 Jul 19;142(1):31-41. PubMed PMID: 10424778.

207: Maehara Y, Sugimachi K, Kurihara M, Taguchi T. [Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group]. Gan To Kagaku Ryoho. 1999 Mar;26(4):476-85. Japanese. PubMed PMID: 10097744.

208: Taguchi T. [Gastrointestinal cancer and oral anticancer agents]. Gan To Kagaku Ryoho. 1999 Feb;26(3):284-94. Review. Japanese. PubMed PMID: 10065090.

209: Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998 Oct;34(11):1715-20. PubMed PMID: 9893658.

210: Naito Y, Kimura S, Yoshizawa M, Ohtake K, Nakajima T, Saku T. Effects of the anticancer drug cocktail "UFT" on metastatic potentials of squamous cell carcinoma (O-1N) in a hamster model. Oral Oncol. 1998 Sep;34(5):326-31. PubMed PMID: 9861336.

211: Fukushima M, Shimamoto Y, Kato T, Uchida J, Yonekura R, Ohshimo H, Shirasaka T. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs. 1998 Oct;9(9):817-23. PubMed PMID: 9840729.

212: Okuda H, Ogura K, Kato A, Takubo H, Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther. 1998 Nov;287(2):791-9. PubMed PMID: 9808711.

213: Oguro A, Nanri M, Miyamoto Y, Ikoma H, Chimori Y, Yamane E, Nishioka B. [Complete remission of liver metastasis from rectal cancer following continuous oral administration of tegafur-uracil after intrahepatic arterial single injection of CDDP and 5-FU]. Gan To Kagaku Ryoho. 1998 Sep;25(11):1767-9. Japanese. PubMed PMID: 9757204.

214: Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol. 1998 Aug;16(8):2877-85. Review. PubMed PMID: 9704742.

215: Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. [Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)]. Gan To Kagaku Ryoho. 1998 Jul;25(8):1151-8. Japanese. PubMed PMID: 9679577.

216: Sakamoto S, Hara Y, Mitamura T, Sassa S, Kudo H, Suzuki S, Kuwa K, Okayasu I, Shinoda H. Additive effects of medroxyprogesterone acetate and 5-fluorouracil derivative on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Anticancer Drugs. 1998 Apr;9(4):351-7. PubMed PMID: 9635926.

217: Konishi T, Idezuki Y, Watanabe H, Haga S, Ushirokouji Y, Shinohara K, Shibusawa M, Bandai Y, Hiraishi M, Murata N, Yabe K, Yamamura T, Yumoto S, Gunji A, Nishigaki M. [Adjuvant chemotherapy with UFT or UFT with OK-432 to patients with gastric and colorectal cancer. Kanto Adjuvant Study Group]. Gan To Kagaku Ryoho. 1998 May;25(6):887-900. Japanese. PubMed PMID: 9617328.

218: Tsunoda A, Shibusawa M, Tsunoda Y, Yokoyama N, Nakao K, Kusano M, Nomura N, Nagayama S, Takechi T. Antitumor effect of S-1 on DMH induced colon cancer in rats. Anticancer Res. 1998 Mar-Apr;18(2A):1137-41. PubMed PMID: 9615778.

219: Watabe T, Okuda H, Ogura K. [Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil]. Yakugaku Zasshi. 1997 Nov;117(10-11):910-21. Review. Japanese. PubMed PMID: 9414600.

220: Honda I, Watanabe S, Fujita Y. [Preoperative adjuvant chemotherapy with oral anticancer agents for stomach cancer]. Gan To Kagaku Ryoho. 1997 Jul;24(9):1109-17. Japanese. PubMed PMID: 9239164.

221: Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi Y, Watabe T. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos. 1997 May;25(5):270-3. PubMed PMID: 9152608.

222: Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi K, Watabe T, Ogura Y. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos. 1997 Feb;25(2):270-3. Corrected and republished in: Drug Metab Dispos. 1997 May;25(5):270-3. PubMed PMID: 9029059.

223: Okabe H, Toko T, Saito H, Nakano K, Fujioka A, Yuasa C, Takeda S, Unemi N. Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2-tetrahydrofuryl)-5-fluorouracil] with uracil, by oral l-leucovorin. Anticancer Res. 1997 Jan-Feb;17(1A):157-64. PubMed PMID: 9066646.

224: Kato Y, Matsukawa S, Muraoka R, Tanigawa N. Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br J Cancer. 1997;75(4):506-11. PubMed PMID: 9052401; PubMed Central PMCID: PMC2063296.

225: Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol. 1997;39(3):205-11. PubMed PMID: 8996521.

226: Hayashi T, Yamaguchi S, Kito S, Tanaka G, Kurokawa K, Hirota T. [An oral repeated dose toxicity study of a new antineoplastic agent S-1 in dogs. I. A 13-week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study]. J Toxicol Sci. 1996 Nov;21 Suppl 3:527-44. Japanese. PubMed PMID: 9021660.

227: Nukatsuka M, Fujioka A, Saito H, Uchida J, Nakano K, Takeda S, Unemi N. Prolongation of survival period and improvement of cancer cachexia by long-term administration of UFT. Cancer Lett. 1996 Jul 12;104(2):197-203. PubMed PMID: 8665488.

228: Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996 Jul;7(5):548-57. PubMed PMID: 8862723.

229: Akiba T, Okeda R, Tajima T. Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture. Acta Neuropathol. 1996 Jul;92(1):8-13. PubMed PMID: 8811119.

230: Nukatsuka M, Fujioka A, Saito H, Uchida J, Takeda S, Unemi N. [Prolongation of survival and antitumor activity of antitumor drugs in murine cancer cachexia model]. Gan To Kagaku Ryoho. 1996 Jun;23(7):887-92. Japanese. PubMed PMID: 8678537.

231: Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996 Jun 1;56(11):2602-6. PubMed PMID: 8653704.

232: Ishikawa T, Ishikawa N, Oota H, Yoshida T, Honma A, Kamimura T, Takeda K, Ishikawa N, Ozaki T. [A case of common bile duct cancer responding to MMC leucovorin, 5-FU, and UFT combination chemotherapy and radiation]. Gan To Kagaku Ryoho. 1996 May;23(6):773-7. Japanese. PubMed PMID: 8645028.

233: Akao S, Iwami N, Oya M, Terada H, Sasaki K, Ishikawa H, Kiumi F. [Evaluation of subrenal capsule assay (SRC) for clinical cancers]. Gan To Kagaku Ryoho. 1996 Apr;23(5):607-13. Japanese. PubMed PMID: 8678520.

234: Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. New anticancer agents in clinical development. Oncology (Williston Park). 1995 Dec;9(12):1321-8; 1331; discussion 1332-4. Review. PubMed PMID: 8771106.

235: Yuasa C, Okabe H, Toko T, Takeda S, Unemi N. [Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil]. Gan To Kagaku Ryoho. 1995 Nov;22(13):1927-32. Japanese. PubMed PMID: 7487122.

236: Saito H, Okabe H, Nakano K, Fujioka A, Toko T, Takeda S, Unemi N. [Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--growth-inhibitory activity of combination against human tumor xenograft]. Gan To Kagaku Ryoho. 1995 Nov;22(13):1919-25. Japanese. PubMed PMID: 7487121.

237: Akao S, Oya M, Ishikawa H, Kiumi F. [Light and electron microscopic examination compared to evaluation by tumor size in subrenal capsule assay for chemosensitivity testing in esophageal cancer]. Gan To Kagaku Ryoho. 1995 Oct;22(12):1813-9. Japanese. PubMed PMID: 7574815.

238: Moriyama A, Murata I, Kuroda T, Yoshikawa I, Tabaru A, Ogami Y, Otsuki M. Pericardiac metastasis from advanced gastric cancer. J Gastroenterol. 1995 Aug;30(4):512-6. PubMed PMID: 7550863.

239: Hirata K. [Combined chemotherapy with 5-FU+cis-platin or UFT+cisplatin]. Gan To Kagaku Ryoho. 1995 Jul;22(8):1009-17. Review. Japanese. PubMed PMID: 7611751.

240: Hayashida S, Hirasawa T, Uchiyama K, Mitsui H, Nasu T, Shinohara Y. [The preventive effect of granisetron on digestive tract symptoms induced by arterial infusion of anticancer and hypertensive agents in combination with radiotherapy--a study of forty patients with bladder cancer]. Gan To Kagaku Ryoho. 1995 Apr;22(5):639-46. Japanese. PubMed PMID: 7717715.

241: Takenaka K, Yoshida K, Nishizaki T, Korenaga D, Hiroshige K, Ikeda T, Sugimachi K. Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg. 1995 Apr;169(4):400-4; discussion 405. PubMed PMID: 7694977.

242: Uchida K, Hayashi T, Shiga T, Hattori K, Nishijima Y, Kasaya S, Shimazui T, Akaza H, Koiso K, Nemoto R, et al. [Treatment of prostatic carcinoma with UFT and leucovorin--basic study using SRCA]. Gan To Kagaku Ryoho. 1994 Nov;21(15):2633-7. Japanese. PubMed PMID: 7979424.

243: Tsunoda A, Shibusawa M, Tsunoda Y, Yasuda N, Nakao K, Kusano M. A model for sensitivity determination of anticancer agents against chemically-induced colon cancer in rats. Anticancer Res. 1994 Nov-Dec;14(6B):2637-42. PubMed PMID: 7872694.

244: Nukatsuka M, Fujioka A, Saito H, Nakano K, Uchida J, Oh-ie S, Nomura N, Takeda S, Unemi N, Ishitani K, et al. [Antitumor and anticachectic activity of UFT in BALB/c mice bearing colon 26 adenocarcinoma]. Gan To Kagaku Ryoho. 1994 Sep;21(12):2013-20. Japanese. PubMed PMID: 8085852.

245: Omura K, Hashimoto T, Kawakami K, Kanehira E, Watanabe T, Hirano K, Watanabe S, Watanabe Y, Shirasaka T. [Innate resistance to thymidylate synthase inhibition after 5-fluorouracil treatment--a rationale of combined use of cisplatin and its optimal administration dose]. Gan To Kagaku Ryoho. 1994 Sep;21(12):2007-11. Japanese. PubMed PMID: 8085851.

246: Kawahara H, Hirai K, Ashikaga K, Yamada Y, Kimura C, Kuroda H, Sato K, Ono M, Aoki T. [The usefulness of pre- and immediately postoperative chemotherapy in colorectal cancer]. Gan To Kagaku Ryoho. 1994 Jul;21(8):1215-9. Japanese. PubMed PMID: 8031164.

247: Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, Sugimachi K. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg. 1994 Jul;168(1):36-40. PubMed PMID: 8024097.

248: Uchida J, Satake H, Saito H, Nakano K, Takeda S, Unemi N. [Experimental evaluation of combination chemotherapy with UFT and cisplatin for lung cancer]. Gan To Kagaku Ryoho. 1994 Jun;21(7):1001-8. Japanese. PubMed PMID: 8210249.

249: Haraguchi M, Furukawa T, Sumizawa T, Akiyama S. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res. 1993 Dec 1;53(23):5680-2. PubMed PMID: 7694792.

250: Yamada Y, Fukatsu H, Honda N, Miyagawa Y, Segawa A. [Clinical study of renal cell carcinoma]. Hinyokika Kiyo. 1993 Dec;39(12):1197-203. Japanese. PubMed PMID: 7506869.

251: Suzuki M, Aida I, Sekiguchi I, Tamada T, Tsuru S. Effect of cyclic cisplatin and etoposide therapy with continuous UFT administration on the recurrence of endometrial cancer in nude mice. Oncology. 1993 Jul-Aug;50(4):209-13. PubMed PMID: 8497371.

252: Watanabe H, Sakakibara N. [Evaluation of long-term administration of oral anti-cancer agent]. Gan To Kagaku Ryoho. 1993 Apr;20(5):637-42. Japanese. PubMed PMID: 8470922.

253: Yamauchi M, Kondo T. [Multi-institutional feasibility study of SDI test for its application to the adjuvant chemotherapy of gastric cancer]. Gan To Kagaku Ryoho. 1993 Mar;20(4):432-9. Japanese. PubMed PMID: 8452380.

254: Giannola LI, Di Stefano V, De Caro V. White beeswax microspheres: a comparative in vitro evaluation of cumulative release of the anticancer agents fluorouracil and ftorafur. Pharmazie. 1993 Feb;48(2):123-6. PubMed PMID: 8475158.

255: Uchida K, Hayashi T, Nishijima Y, Kasaya T, Akaza H, Koiso K, Nemoto R, Harada M. [Subrenal capsule assay of nude mice for testing the effectiveness of UFT for rat prostatic carcinoma (R3327)]. Gan To Kagaku Ryoho. 1993 Feb;20(2):229-33. Japanese. PubMed PMID: 8434960.

256: Fujita F, Fujita M, Inaba H, Taguchi T. [Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration]. Gan To Kagaku Ryoho. 1993 Feb;20(2):223-8. Japanese. PubMed PMID: 8434959.

257: Taguchi T. [Development of fluorinated pyrimidines in Japan]. Gan To Kagaku Ryoho. 1993 Jan;20(1):10-8. Review. Japanese. PubMed PMID: 8422172.

258: Sakamoto O, Mori H, Kitaichi K, Koda A, Kato T. Antitumor activity of two novel low immunosuppressive fluoropyrimidines UK-21 and UK-25. Jpn J Pharmacol. 1992 Aug;59(4):469-76. PubMed PMID: 1434142.

259: Tseng CC, Nio Y, Tsubono M, Kawabata K, Masai Y, Hayashi H, Fukumoto M, Tobe T. The role of additional chemotherapy with oral UFT in intravenous combination chemotherapy with cisplatin and 5-fluorouracil for human gastric cancer xenograft lines of well- and poorly- differentiated adenocarcinomas transplanted in nude mice. Anticancer Res. 1992 Jul-Aug;12(4):1295-9. PubMed PMID: 1503424.

260: Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology. 1992 Jul;16(1):112-7. PubMed PMID: 1377657.

261: Nakashima T, Miyagi M, Kusumoto T. [Chemosensitivity of head and neck squamous cell carcinomas using subrenal capsule assay--comparative assay of 5-FU, FT, UFT, and HCFU and immunohistochemical study]. Nippon Jibiinkoka Gakkai Kaiho. 1992 Jan;95(1):95-103. Japanese. PubMed PMID: 1545316.

262: Inokuchi K. Prolonged survival of stomach cancer patients after extensive surgery and adjuvant treatment: an overview of the Japanese experience. Semin Surg Oncol. 1991 Nov-Dec;7(6):333-8. Review. PubMed PMID: 1759080.

263: Fujita K, Munakata A. [Experience of oral hormone-chemotherapy in prostatic cancer]. Gan To Kagaku Ryoho. 1991 Aug;18(10):1691-4. Japanese. PubMed PMID: 1872625.

264: Yamada K, Hase S, Yoshimura A, Haruyama K, Katsura Y, Sameshima T, Niwa K, Ishizawa T, Shimazu H. [Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration]. Gan To Kagaku Ryoho. 1990 Dec;17(12):2333-7. Japanese. PubMed PMID: 2260869.

265: Fukamura T, Umeno T, Jyozaki H, Haruta J, Okamoto K, Hashimoto M, Arima S, Shimura H. [Study of tissue drug concentration of fluorinated pyrimidine anticancer drugs--comparison of 5'DFUR and UFT]. Gan To Kagaku Ryoho. 1990 Sep;17(9):1887-92. Japanese. PubMed PMID: 2144106.

266: Sakuramoto K, Okajima K, Iga C, Nishimura J, Toyoda M, Kawashima Y. [A case of advanced gastric cancer with Virchow's node metastasis, responding to concomitant plasma exchange and immunochemotherapy]. Gan To Kagaku Ryoho. 1989 Dec;16(12):3795-9. Japanese. PubMed PMID: 2512860.

267: Arima S, Futami K, Yoshimura S, Shimura H. Distributions of tegafur in tissues of gastric adenocarcinoma patients: tissue uptakes and concentrations in plasma after oral and rectal administrations. Jpn J Clin Oncol. 1989 Sep;19(3):237-41. PubMed PMID: 2509764.

268: Kimura M, Koida T. [Changes in lymphocyte subsets with post-operative chemotherapy in breast carcinoma--a study of using two color analysis]. Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 1):2621-5. Japanese. PubMed PMID: 2505684.

269: Kashii A, Kogure H. [A multicenter comparative study in patients with liver metastasis to compare tegafur in new forms with existing drugs. SF-RC.SF-SP Comparative Study Group]. Gan To Kagaku Ryoho. 1989 Jul;16(7):2387-92. Japanese. PubMed PMID: 2502074.

270: Hayashi T, Yamada T, Kitagawa S, Nakagawa M. [A case of biliary tract obstruction due to metastatic hepatic cancer, in which topical injection of CDDP and ADM into PTCD with concomitant use of UFT resulting in partial reopening of biliary tract]. Gan To Kagaku Ryoho. 1989 Jun;16(6):2293-6. Japanese. PubMed PMID: 2500071.

271: Arima S, Futami K, Toriya H, Shimura H. The uptake of anticancer drugs by tumor tissues and lymph node and the effectiveness of postoperative adjuvant chemotherapy on survival time. Jpn J Surg. 1989 Mar;19(2):177-81. PubMed PMID: 2498562.

272: Nishiyama M, Takagami S, Kirihara Y, Saeki T, Hirabayashi N, Nosoh Y, Niimoto M, Hattori T. The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay. Jpn J Surg. 1988 Nov;18(6):725-8. PubMed PMID: 2977626.

273: Akiyoshi T, Arinaga S, Takamuku K, Wada T, Koba F, Tsuji H. A trial of postoperative adjuvant combination chemo-immunotherapy for stage IV gastric carcinoma. Jpn J Surg. 1988 Sep;18(5):521-6. PubMed PMID: 3230726.

274: Arima S, Futami K, Shigeta M, Yoshimura S, Tateishi S, Shinohara T, Sakaida R. [Uptake of anticancer drugs by target organs and the usefulness of adjuvant chemotherapy]. Gan To Kagaku Ryoho. 1988 Aug;15(8):2279-83. Japanese. PubMed PMID: 3136699.

275: Urabe N, Momiki S, Shiba M, Yamaguchi Y. [A sensitivity test of UFT and FT-207 against human pulmonary cancer using nude mice]. Gan To Kagaku Ryoho. 1988 Aug;15(8):2224-8. Japanese. PubMed PMID: 3136694.

276: Imaoka S, Sasaki Y, Shibata T, Fujita M, Ishikawa O, Ohigashi H, Furukawa H, Koyama H, Iwanaga T, Hirose N. [Anticancer effect of UFT in intrahepatic recurrence with tumor embolus in the left portal vein after hepatectomy of hepatoma--a case report]. Gan To Kagaku Ryoho. 1988 Aug;15(8):2335-8. Japanese. PubMed PMID: 2841906.

277: Komatsumoto M, Li S, Hamada J, Takeichi N, Hosokawa M, Okayasu T, Tanabe T, Kobayashi H. [Inhibitory effect of UFT on postoperative lung metastasis of mammary adenocarcinoma in SHR rats]. Gan To Kagaku Ryoho. 1988 May;15(5):1739-45. Japanese. PubMed PMID: 3130810.

278: Nishiyama M, Niimi K, Takagami S, Hirabayashi N, Yamaguchi M, Saeki T, Yoshinaka K, Wang DC, Niimoto M, Hattori T. Combined effects of UFT with other anticancer agents using in vivo chemosensitivity tests. Jpn J Surg. 1988 Jan;18(1):93-7. PubMed PMID: 3133515.

279: Kitajima M, Ikeda Y, Kiuchi T, Okada N, Fukuzumi N, Kaga F. [The effect of tegafur suppository and glutathione in patients with gastric and colonic cancer with special reference to the histopathological anticancer effect]. Gan To Kagaku Ryoho. 1987 Nov;14(11):3131-9. Japanese. PubMed PMID: 3118814.

280: Tsukagoshi S. [A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)]. Gan To Kagaku Ryoho. 1987 Oct;14(10):2977-82. Japanese. PubMed PMID: 2959207.

281: Ota K, Taguchi T, Kimura K. [Report on nationwide pooled data and cohort investigation in UFT phase II study]. Gan To Kagaku Ryoho. 1987 Sep;14(9):2749-57. Japanese. PubMed PMID: 3115185.

282: Sugawara T, Sakuramoto T, Fukushima S. [Complete remission of lung metastasis of renal cell carcinoma by (UFT) therapy]. Hinyokika Kiyo. 1987 Aug;33(8):1232-5. Japanese. PubMed PMID: 3122543.

283: Suga S, Ina K, Horiuchi Y, Suzui N, Hashizume H, Yasue K, Usami Y, Takahashi Y, Ichihara S, Yokoyama Y. [Futraful and UFT, their metabolic characteristics]. Gan To Kagaku Ryoho. 1987 Jul;14(7):2228-34. Japanese. PubMed PMID: 3111380.

284: Satomi A, Takada Y, Ishida K. [Experimental study of intralymphatic chemotherapy in rabbits]. Gan To Kagaku Ryoho. 1987 Jul;14(7):2262-8. Japanese. PubMed PMID: 2955746.

285: Hanaue H, Kurosawa T, Kitano Y, Miyakawa S, Nemoto A, Yamamoto H, Asagoe T, Takada T, Yasuda H, Shikata J. Anticancer drug distribution in lymph and blood during adjuvant chemotherapy after surgery for gastric carcinoma. A study with a combined preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil. Cancer. 1987 May 1;59(9):1571-6. PubMed PMID: 3103905.

286: Nishino S, Kikuchi Y, Takahashi K, Yoshikawa H, Asano A. [Three cases of adenocarcinoma of the lower esophagus and cardia showing marked regression after radiotherapy with FT-207]. Gan To Kagaku Ryoho. 1987 Apr;14(4):1160-3. Japanese. PubMed PMID: 3105470.

287: Kurihara M, Izumi T, Ichiki H, Tasaka K, Orima H, Miyasaka K, Sasaki Y. [UFT therapy of experimental gastric cancer in beagles induced by ENNG]. Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 2):881-8. Japanese. PubMed PMID: 3105462.

288: Fujita F, Fujita M, Hirai T, Taguchi T. [Evaluation by multiple regression analysis of factors influencing the chemosensitivity of human tumors xenografted into nude mice]. Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 1):618-25. Japanese. PubMed PMID: 2950823.

289: Nishiyama M, Niimi K, Yamaguchi M, Hirabayashi N, Nosoh Y, Tohge T, Niimoto M, Hattori T. [In vivo chemosensitivity test for UFT and FT-207. I--Subrenal capsule assay]. Gan To Kagaku Ryoho. 1987 Jan;14(1):109-13. Japanese. PubMed PMID: 3099648.

290: Kagawa S, Takigawa H, Aga Y, Kurokawa K. [Experimental study of UFT in prostatic carcinoma (DU-145) in nude mice]. Gan To Kagaku Ryoho. 1986 Dec;13(12):3408-12. Japanese. PubMed PMID: 3098182.

291: Ando B, Inoue K, Koga S, Ibayashi H, Ando S. [An unresectable case of hepatoma completely disappearing after oral administration of an anticancer drug (UFT)]. Gan To Kagaku Ryoho. 1986 Oct;13(11):3261-5. Japanese. PubMed PMID: 3022652.

292: Maeda T. [Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment]. Nippon Sanka Fujinka Gakkai Zasshi. 1986 Sep;38(9):1515-26. Japanese. PubMed PMID: 3095465.

293: Kimura M, Koida T, Sugihara S. [The concentration in the tissue and antitumor effect of anticancer drug--assessment of breast cancer with UFT or FT-207]. Gan To Kagaku Ryoho. 1986 Jul;13(7):2389-92. Japanese. PubMed PMID: 3089177.

294: Niimoto M, Hirono M, Hattori T, Nakajima T, Hirata K, Iwanaga T, Kimura T, Nakazato H, Inokuchi K, Sugimachi K, et al. [Secondary malignancies after gastrectomy for gastric cancer]. Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1475-83. Japanese. PubMed PMID: 3729464.

295: Tamada R. [Surgery and adjuvant therapy of gastric cancer]. Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1555-63. Japanese. PubMed PMID: 3089173.

296: Okazaki N, Yoshino M, Yoshida T, Hizikata A, Hasegawa H. [Systemic chemotherapy of hepatocellular carcinoma]. Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1584-8. Japanese. PubMed PMID: 3015033.

297: Hamada S, Hirayama R, Matsumura J, Takagi Y, Miyanaga T, Aoki N, Mishima Y. Longer survival and fewer metastases by levamisole and tegafur in 1, 2-dimethylhydrazine-induced murine colonic cancers. Bull Tokyo Med Dent Univ. 1985 Jun;32(2):67-75. PubMed PMID: 3933845.

298: Gupta RS. Cross-resistance of vinblastine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs. Cancer Treat Rep. 1985 May;69(5):515-21. PubMed PMID: 2860971.

299: Yoshimori M, Tajiri H, Nakamura K, Ozaki H. [Chemotherapy of pancreatic cancer]. Gan To Kagaku Ryoho. 1985 Feb;12(2):227-34. Japanese. PubMed PMID: 3155930.

300: Tanaka J, Inuyama Y, Fujii M, Takaoka T, Hosoda H, Saito S. Clinical trials on UFT in the treatment of head and neck cancer. Auris Nasus Larynx. 1985;12 Suppl 2:S261-6. PubMed PMID: 3939186.

301: Kameda C, Tanaka T, Shiomi M, Saka M, Katsu K, Itoh S. [Evaluation of tegafur encapsulated with slow-releasing granules (SF-SP) for patients with cancer of the digestive organs]. Gan To Kagaku Ryoho. 1984 Dec;11(12 Pt 1):2526-30. Japanese. PubMed PMID: 6439120.

302: Azuma N, Kamano T, Yuasa S, Tamura J, Katami A, Sato T, Kishino H, Mizukami K, Kidokoro T. [Clinical trials of plasma exchange therapy in patients with recurrent colon cancer]. Gan To Kagaku Ryoho. 1984 Sep;11(9):1801-8. Japanese. PubMed PMID: 6433804.

303: Kurokawa T, Iwasa H, Mimura K, Terashima H, Hiraide H, Mizoguchi O, Kanabe S, Tamaki K, Kadota T, Hatsuse K, et al. [Intraperitoneal administration of FT-207 for mouse peritonitis carcinomatosa]. Gan To Kagaku Ryoho. 1984 Apr;11(4):881-7. Japanese. PubMed PMID: 6426398.

304: Fujita H. [Chemical modification of anticancer agents from viewpoints of their pharmacokinetics]. Gan To Kagaku Ryoho. 1984 Mar;11(3 Pt 2):733-40. Japanese. PubMed PMID: 6424579.

305: Yamamoto J, Haruno A, Yoshimura Y, Unemi N, Kunimune Y, Yamashita K, Morita K. Effect of coadministration of uracil on the toxicity of tegafur. J Pharm Sci. 1984 Feb;73(2):212-4. PubMed PMID: 6423805.

306: Yamada F, Kagami H, Fukutome A, Mastumine T, Miura T. [Experience of a combination chemotherapy consisting of 5-FU, MMC, and FT-207--side effects against kidney]. Gan To Kagaku Ryoho. 1983 Sep;10(9):2049-54. Japanese. PubMed PMID: 6412636.

307: Wakui A, Taguchi T. [Analysis of factors affecting clinical cancer chemotherapy]. Gan No Rinsho. 1983 Aug;29(10):1199-204. Japanese. PubMed PMID: 6415312.

308: Arima S, Futami K, Kinashi M, Shigeta M, Jyozaki H, Shimura H. [Study on the correlation between tissue uptake of anticancer agents and prognosis -- with special reference to Tegafur]. Gan To Kagaku Ryoho. 1983 Aug;10(8):1788-95. Japanese. PubMed PMID: 6411003.

309: Komuro K, Hara Y, Fujii Y, Nagayama A, Kobayashi T, Gotoh M, Hagiwara H, Nakamura R, Nagasaki Y, Kataoka J, Andoh H, Nakamura K. [Clinical study on preoperative chemotherapy of primary breast cancer. 2--A comparative study of CPA + FT-207 (5-FUDS) and CPA + FT-207 (5-FUDS) + MMC]. Gan To Kagaku Ryoho. 1983 Jun;10(6):1454-60. Japanese. PubMed PMID: 6307168.

310: Komuro K, Hara Y, Fujii Y, Yamazaki M, Amano R, Hashiguchi F, Sakamoto R, Nakamura R, Shimada A, Kurata T, Ando H, Nakamura K. [Clinical study of preoperative chemotherapy of primary breast cancer. 1. Efficacy of a combined use of CPA (endoxan) and FT-207 (or 5-FU dry syrup)]. Gan To Kagaku Ryoho. 1982 Dec;9(12):2180-5. Japanese. PubMed PMID: 6820892.

311: Hamada S. [Anticancer effect of levamisole and tegafur on 1,2-dimethylhydrazine (DMH)-induced colonic cancers in rats]. Nippon Gan Chiryo Gakkai Shi. 1982 Oct 20;17(7):1925-35. Japanese. PubMed PMID: 6819333.

312: Powis G. Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs. Cancer Treat Rev. 1982 Jun;9(2):85-124. Review. PubMed PMID: 6181872.

313: Nakazawa I, Goto Y, Ouchi E, Nomura N, Suzuki N, Kikuchi T. [A clinical investigation of the combination therapy of 1-(2-tetrahydrofuryl)-5-fluorouracil (FH) fine granules and 5-FU dry syrup]. Gan To Kagaku Ryoho. 1982 Apr;9(4):722-5. Japanese. PubMed PMID: 6820906.

314: Furue H. [Clinical experiences with UFD-1]. Gan To Kagaku Ryoho. 1982 Apr;9(4):672-4. Japanese. PubMed PMID: 6820905.

315: Kaga F, Kitajima M, Ikeda Y, Seki M, Yagita A, Sohma S, Fukuzumi N. [Evaluation of pre-operative chemotherapy using FT-207 suppositories combined with glutathione--with special reference to histopathological antitumor effect]. Gan To Kagaku Ryoho. 1982 Mar;9(3):489-95. Japanese. PubMed PMID: 6820899.

316: Suga S, Kimura K, Yokoyama Y, Isobe K, Yoshida Y, Takada T, Sato A, Kuwabara T, Iwase H. Studies on the designing of chemotherapy for gastric cancer in man, based on the tumor tissue concentration of anticancer agents. Gastroenterol Jpn. 1982;17(4):295-300. PubMed PMID: 6216137.

317: Suzuki S, Hongu Y, Fukazawa H, Ichihara S, Shimizu H. Tissue distribution of 5'-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats. Gann. 1980 Apr;71(2):238-45. PubMed PMID: 6451469.

318: Taguchi T. Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1). Recent Results Cancer Res. 1980;70:133-45. PubMed PMID: 6766562.

319: Soejima S. [Long-term oral administration of anticancer drug (author's transl)]. Nippon Gan Chiryo Gakkai Shi. 1979 Dec 20;14(7):1136-45. Japanese. PubMed PMID: 120403.

320: Kinami Y, Odagiri S, Shinmura K, Miyazaki H. [Experimental study on the effects of local administration of anticancer drug to the regional lymph nodes (author's transl)]. Nippon Gan Chiryo Gakkai Shi. 1978 Aug 20;13(4):387-93. Japanese. PubMed PMID: 361908.

321: Honda H. [A clinicopathological study on preoperative anticancer chemotherapy for gastric cancer (author's transl)]. Nippon Geka Hokan. 1978 May 1;47(3):333-63. Japanese. PubMed PMID: 354546.

322: Kaibara N, Soejima K, Nakamura T, Inokuchi K. Postoperative long term chemotherapy for advanced gastric cancer. Jpn J Surg. 1976 Jun;6(2):54-9. PubMed PMID: 825677.